Posters
- Resources
- Posters
Always at the forefront of the dynamic patient-derived xenograft (PDX) market, Champions Oncology has emerged as a respected key opinion leader on the utilization and benefits of PDX models in oncology drug development.
Clinical Flow Cytometry
Hematological Malignancies
Humanized Models
Lumin Acuity
Solid Tumor PDX Models
Raptamer-Drug Conjugates as Molecularly Targets Cancer Therapeutics - AACR 2023
Combining Multiomics and Histological Assessment to Identify Patient-derived Xenograft Models of Invasive Lobular Carcinoma - San Antonio Breast Cancer Symposium 2022
TumorGraft3D & Co-Culture Platforms
Bioluminescent 3D Tumors with Immune Cell Co-culture for High Throughput Screening (HTS) - AACR 2024
A Novel 3D Co-Culture Platform for Patient-Specific Immune-Oncology Treatment - AACR 2024
An Innovative PDX and Patient-derived 3D Platform for Improved Translatability of New Medical Entities - AACR 2024
A Novel TumorGraft3D immune co-culture platform for high throughput immune-oncology screening - SITC 2023
Identification of synergistic combination of molecular targeted agents and chemotherapy using TumorGraft3D and Lumin platform - Tumor Models Boston 2023
Unique 3D Organoids Autologous TIL Co-Culture Platform Enables High Throughput Immune-Oncology Drug Response Studies - AACR 2021
Development of a 3D Organoid Autologous TIL Co-Culture Platform for High Throughput Immuno-Oncology Studies - SITC 2020